Inhibition Of CD147 Expression Reduces Tumor Cell Invasion In Human Prostate Cancer Cell Line Via RNA Interference

Prostate cancer (CaP) is the most common non-dermatological malignancy and the second leading cause (after lung cancer) of cancer-related death in men in the United States of America (USA). In the USA, the incidence of CaP is estimated to be 232,090 new cases in 2005, with 30,350 estimated deaths. Despite Radical Prostatectomy (RP) is the most appropriate treatment for patients with localized CaP, the risk of biochemical disease recurrence for these patients is about 25%. Even in this era of aggressive screening, however, a large proportion of newly diagnosed CaPs will be classified as tumors at "high risk" of disease relapse despite definitive treatments. Because the tumors progress rapidly and most death is caused by metastases that are resistant to conventional therapies, the optimal therapy for patients with these tumors has yet to be defined.CD147, also named extracelluar matrix metalloproteinase inducer (EMMPRIN), is a transmembrane glycosylated member of the immunoglobulin superfamily molecules expressed on the cell surface of most tumor cells, and its expression was reported to correlate with tumor progression and invasion. CD147 contributes to tumor invasion and metastasis...